Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246090 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 298
- Enrollment target
NCT00246090: Completed Phase 2 study, sponsored by Eisai.
NCT00246090 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 298 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (124% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00246090, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 298 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of E7389 in Patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine as prior therapy, and who are refractory to the last prior therapy for their disease.
Primary Outcome
Based on Response Evaluation Criteria in Solid Tumors (RECIST), consisting of complete response (CR) plus partial response (PR). Defined as the best response from the start of treatment until disease progression or recurrence. Lesions measured by computed tomography (CT) scan and magnetic resonance imaging (MRI). Objective response rate: complete response (CR-disappearance of all lesions)+ partial response (PR-30% decrease in lesion diameter), Progressive Disease (PD-20% increase in lesion diame
Interventions
- DRUG E7389
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
What the finished NCT00246090 record still lists
NCT00246090 is an interventional study that assigns participants to a tested intervention. The registered 298 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (124% higher).
The record links to 0 conditions, and to 1 intervention - of which E7389 is the first listed.
NCT00246090 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00246090 about?
NCT00246090 is a clinical study titled "A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine". The purpose of this study is to evaluate the efficacy and safety of E7389 in Patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine as prior therapy, and who are refractory to the last prior therapy for their disease.
What is the current status of trial NCT00246090?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 298 participants. The study started on 2005-10. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00246090?
The interventions under investigation include: E7389 (DRUG).
Who is sponsoring clinical trial NCT00246090?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00246090's enrollment target sits among peer trials
298 188th of 2000 higher than 1,813 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
- NCT06754215 · 298 participants · NA
Smoking Cessation Intervention Development for Homeless Youth
- NCT06780111 · 298 participants · Phase 1
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- NCT07209358 · 298 participants · NA
EDX110 Randomized Control Trial for Treatment of DFUs
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia